JP6339548B2 - 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法 - Google Patents

微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法 Download PDF

Info

Publication number
JP6339548B2
JP6339548B2 JP2015206158A JP2015206158A JP6339548B2 JP 6339548 B2 JP6339548 B2 JP 6339548B2 JP 2015206158 A JP2015206158 A JP 2015206158A JP 2015206158 A JP2015206158 A JP 2015206158A JP 6339548 B2 JP6339548 B2 JP 6339548B2
Authority
JP
Japan
Prior art keywords
protein
membrane
extracellular body
schizochytrium
microalgal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015206158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016047055A (ja
Inventor
アン−セシル ブイ． バイン
アン−セシル ブイ． バイン
ジェイムズ ケーシー リップマイアー
ジェイムズ ケーシー リップマイアー
カーク エミル アプト
カーク エミル アプト
ロス エリック ザークレ
ロス エリック ザークレ
Original Assignee
サノフィ ワクチン テクノロジーズ エス．エー．エス．
サノフィ ワクチン テクノロジーズ エス．エー．エス．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ ワクチン テクノロジーズ エス．エー．エス．, サノフィ ワクチン テクノロジーズ エス．エー．エス． filed Critical サノフィ ワクチン テクノロジーズ エス．エー．エス．
Publication of JP2016047055A publication Critical patent/JP2016047055A/ja
Application granted granted Critical
Publication of JP6339548B2 publication Critical patent/JP6339548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015206158A 2009-12-28 2015-10-20 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法 Active JP6339548B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29044109P 2009-12-28 2009-12-28
US29046909P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012547250A Division JP5838496B6 (ja) 2009-12-28 2010-12-28 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018091280A Division JP6666950B2 (ja) 2009-12-28 2018-05-10 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法

Publications (2)

Publication Number Publication Date
JP2016047055A JP2016047055A (ja) 2016-04-07
JP6339548B2 true JP6339548B2 (ja) 2018-06-06

Family

ID=44307127

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015206158A Active JP6339548B2 (ja) 2009-12-28 2015-10-20 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2018091280A Active JP6666950B2 (ja) 2009-12-28 2018-05-10 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2020027762A Active JP7745996B2 (ja) 2009-12-28 2020-02-21 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2023072538A Active JP7585382B2 (ja) 2009-12-28 2023-04-26 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2025081042A Pending JP2025114812A (ja) 2009-12-28 2025-05-14 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018091280A Active JP6666950B2 (ja) 2009-12-28 2018-05-10 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2020027762A Active JP7745996B2 (ja) 2009-12-28 2020-02-21 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2023072538A Active JP7585382B2 (ja) 2009-12-28 2023-04-26 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP2025081042A Pending JP2025114812A (ja) 2009-12-28 2025-05-14 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法

Country Status (9)

Country Link
US (3) US20110189228A1 (cg-RX-API-DMAC10.html)
EP (3) EP4130273B1 (cg-RX-API-DMAC10.html)
JP (5) JP6339548B2 (cg-RX-API-DMAC10.html)
CN (2) CN107746869A (cg-RX-API-DMAC10.html)
AU (4) AU2010343095B2 (cg-RX-API-DMAC10.html)
CA (3) CA2785971C (cg-RX-API-DMAC10.html)
EA (1) EA022841B1 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN06277A (cg-RX-API-DMAC10.html)
WO (1) WO2011090731A1 (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350854B (en) 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
US8637651B2 (en) 2009-03-16 2014-01-28 Dsm Ip Assets B.V. Protein production in microorganisms of the phylum labyrinthulomycota
KR20120101572A (ko) * 2009-12-28 2012-09-13 메리얼 리미티드 재조합 ｎｄｖ 항원 및 이의 용도
EA030095B1 (ru) * 2009-12-28 2018-06-29 ДиЭсЭм АйПи АССЕТС Б.В. Получение белка гемагглютинин-нейраминидазы в микроводорослях
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
DK2683824T3 (en) 2011-03-07 2018-06-18 Dsm Nutritional Products Ag GENMANIPULATION OF THRAUSTOCHYTRIDE MICROORGANISMS
BR112014004188A2 (pt) * 2011-08-24 2017-03-21 Novozymes Inc método para obter transformantes positivos de uma célula hospedeira fúngica filamentosa, célula hospedeira fúngica filamentosa, método para produzir múltiplos polipeptídeos recombinantes, e, construto em tandem
CA2879680A1 (en) 2012-07-24 2014-01-30 Bp Corporation North America Inc. Xylose isomerases and their uses
WO2014045191A2 (en) * 2012-09-18 2014-03-27 Myko Tech Private Limited Extracellular polysaccharides from labyrinthulomycetes with broad-spectrum antiviral activities
DK179981B1 (en) * 2014-10-02 2019-11-29 Evonik Degussa Gmbh Process for producing a PUFA-containing feedstuff by extruding a PUFA-containing biomass
DK179843B1 (en) 2014-10-02 2019-07-31 Evonik Degussa Gmbh Method for raising animals
ES2870093T3 (es) 2014-10-02 2021-10-26 Evonik Operations Gmbh Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos
WO2016050554A1 (de) 2014-10-02 2016-04-07 Evonik Degussa Gmbh Pufas enthaltendes futtermittel mit hoher abriebfestigkeit und hoher wasserstabilität
CA2977271A1 (en) 2015-03-02 2016-09-09 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
EP3322796A4 (en) 2015-07-13 2019-03-27 Mara Renewables Corporation IMPROVEMENT OF MICROGENONAL FLUID CHANGES OF XYLOSE
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
EP3512948A4 (en) * 2016-09-09 2020-05-13 Cornell University ADMINISTRATION OF NUCLEIC ACIDS, PROTEINS AND SMALL MOLECULES IN GLASS-LIKE VESICULAR BODIES
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
WO2018098001A1 (en) * 2016-11-27 2018-05-31 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
EP3762485A4 (en) * 2018-03-05 2021-12-08 Conagen Inc. ORGANISMS AND PROCESSES FOR THE PRODUCTION OF LOW SULPHATION GLYCOMOLECULES
CN112369128A (zh) 2018-06-27 2021-02-12 住友电气工业株式会社 柔性印刷线路板的前体、制造柔性印刷线路板的方法、聚光型光伏发电模块和发光模块
EP3852608A4 (en) 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
JP7637903B2 (ja) * 2019-11-21 2025-03-03 パナソニックＩｐマネジメント株式会社 改変シアノバクテリア、改変シアノバクテリアの製造方法、及び、タンパク質の製造方法
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
US20240287443A1 (en) * 2021-06-24 2024-08-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
IL312545A (en) 2021-11-05 2024-07-01 Sanofi Pasteur Inc Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them
CN118302190A (zh) 2021-11-05 2024-07-05 赛诺菲 包含血凝素和神经氨酸酶的杂合多价流感疫苗及其使用方法
AU2022399571A1 (en) 2021-11-30 2024-07-11 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CA3258773A1 (en) 2022-06-14 2023-12-21 Semmelweis Egyetem EXTRACELLULAR VESICLES INTENDED FOR USE IN THERAPY
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5962298A (en) * 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
KR20000075076A (ko) * 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
BRPI0111830B8 (pt) * 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
TWI350854B (en) * 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
WO2003086453A1 (en) 2002-04-12 2003-10-23 Ilaria Capua Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
AU2004265232A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
ES2533382T3 (es) * 2004-05-25 2015-04-09 Medimmune, Llc Variantes de la hemaglutinina y la neuraminidasa de influenza
WO2006013572A2 (en) * 2004-08-05 2006-02-09 Ben Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP4796786B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN101605558A (zh) * 2005-08-16 2009-12-16 夏威夷生物技术公司 流感重组亚单位疫苗
WO2007100584A2 (en) * 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
JP2009529891A (ja) * 2006-03-15 2009-08-27 マーテック バイオサイエンシーズ コーポレーション 多価不飽和脂肪酸を含む植物種子油
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
US20100310604A1 (en) * 2007-11-27 2010-12-09 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
MX2010010058A (es) * 2008-03-19 2010-09-30 Hexion Specialty Chemicals Inc Modificador para formulaciones de cemento y concreto y metodos para su preparacion.
US8637651B2 (en) 2009-03-16 2014-01-28 Dsm Ip Assets B.V. Protein production in microorganisms of the phylum labyrinthulomycota
KR20120101572A (ko) * 2009-12-28 2012-09-13 메리얼 리미티드 재조합 ｎｄｖ 항원 및 이의 용도
EA030095B1 (ru) * 2009-12-28 2018-06-29 ДиЭсЭм АйПи АССЕТС Б.В. Получение белка гемагглютинин-нейраминидазы в микроводорослях

Also Published As

Publication number Publication date
CA3028175A1 (en) 2011-07-28
EP2519635B1 (en) 2018-11-21
IN2012DN06277A (cg-RX-API-DMAC10.html) 2015-09-25
CN102822343A (zh) 2012-12-12
JP2013515503A (ja) 2013-05-09
AU2017202195A1 (en) 2017-04-20
CA3153553A1 (en) 2011-07-28
JP2020096635A (ja) 2020-06-25
AU2017202195B2 (en) 2019-04-18
EP4130273C0 (en) 2024-06-12
CN107746869A (zh) 2018-03-02
EA022841B1 (ru) 2016-03-31
EP3505632B1 (en) 2022-08-03
CA2785971A1 (en) 2011-07-28
AU2010343095A1 (en) 2012-08-09
CN102822343B (zh) 2017-10-20
AU2019206054B2 (en) 2022-03-10
EP3505632A1 (en) 2019-07-03
JP2025114812A (ja) 2025-08-05
JP7745996B2 (ja) 2025-09-30
JP2023101420A (ja) 2023-07-20
JP2018121660A (ja) 2018-08-09
WO2011090731A1 (en) 2011-07-28
CA2785971C (en) 2019-02-12
AU2010343095B2 (en) 2017-01-05
US20150110826A1 (en) 2015-04-23
JP6666950B2 (ja) 2020-03-18
JP7585382B2 (ja) 2024-11-18
AU2022203980B2 (en) 2024-12-12
JP5838496B2 (ja) 2016-01-06
EA201290567A1 (ru) 2013-02-28
EP2519635A4 (en) 2013-06-26
AU2019206054A1 (en) 2019-08-08
EP4130273A1 (en) 2023-02-08
EP4130273B1 (en) 2024-06-12
EP2519635A1 (en) 2012-11-07
AU2022203980A1 (en) 2022-06-30
US20200063174A1 (en) 2020-02-27
US20110189228A1 (en) 2011-08-04
CA3028175C (en) 2022-05-24
JP2016047055A (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
JP7745996B2 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP5838473B2 (ja) 微細藻類におけるヘマグルチニン−ノイラミニダーゼタンパク質の産生方法
EA034733B1 (ru) Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
KR20210024625A (ko) 인플루엔자 바이러스 헤마글루티닌 돌연변이들
CN117244048A (zh) 一种禽流感病毒mRNA疫苗及其制备方法和应用
CN111315408A (zh) 在嗜热毁丝霉(myceliophthora thermophila)中生产流感疫苗
JP5838496B6 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180510

R150 Certificate of patent or registration of utility model

Ref document number: 6339548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250